Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.48 |
| ▸ | JAK2 | O60674 | 12/20 | 0.44 |
| ▸ | AURKA | O14965 | 4/20 | 0.44 |
| ▸ | JAK3 | P52333 | 3/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1657539 | 0.92 | AURKA (0.48) | RPS6KA3JAK2AURKAJAK3CDC7 | |
| SCHEMBL4290781 | 0.92 | RPS6KA3 (0.47) | RPS6KA3JAK2AURKAJAK3BRD4 | |
| SCHEMBL4284006 | 0.91 | JAK2 (0.46) | RPS6KA3JAK2AURKAJAK3CDC7 | |
| SCHEMBL4293676 | 0.89 | RPS6KA3 (0.45) | RPS6KA3JAK2AURKAJAK3SYK | |
| SCHEMBL4288912 | 0.89 | PTK2 (0.44) | RPS6KA3JAK2AURKACDK2BRD4 | |
| SCHEMBL1657504 | 0.88 | RPS6KA3 (0.47) | RPS6KA3JAK2AURKAJAK3BRD4 | |
| SCHEMBL4288934 | 0.88 | RPS6KA3 (0.47) | RPS6KA3JAK2AURKAJAK3EGFR | |
| SCHEMBL4287613 | 0.87 | RPS6KA3 (0.46) | RPS6KA3JAK2AURKAJAK3FGFR1 | |
| SCHEMBL4288417 | 0.87 | JAK2 (0.47) | RPS6KA3JAK2AURKAJAK3BRD4 | |
| SCHEMBL1654501 | 0.87 | RPS6KA3 (0.57) | RPS6KA3JAK2AURKAJAK3CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | claimed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | RPS6KA3 303/4885JAK2 2/4885AURKA 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.